EYPT - EyePoint Pharmaceuticals, Inc.

12.5
-0.560   -4.480%

Share volume: 751,225
Last Updated: 03-27-2026
Measuring And Control Equipment/Lab Analytical Instruments: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$13.06
-0.56
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
12%
Profitability 0%
Dept financing 20%
Liquidity 58%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.57%
1 Month
-31.84%
3 Months
-31.32%
6 Months
-11.03%
1 Year
114.41%
2 Year
-39.53%
Key data
Stock price
$12.50
P/E Ratio 
N/A
DAY RANGE
$12.44 - $13.12
EPS 
-$3.17
52 WEEK RANGE
$3.91 - $19.11
52 WEEK CHANGE
$130.63
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
83.432 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$842,394
AVERAGE 30 VOLUME 
$1,343,999
Company detail
CEO: Nancy S. Lurker
Region: US
Website: eyepointpharma.com
Employees: 120
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Measuring And Control Equipment/Lab Analytical Instruments
Sector: Manufacturing

EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

Recent news